Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report)’s share price shot up 2.3% during mid-day trading on Monday . The stock traded as high as $1.81 and last traded at $1.79. 36,311 shares changed hands during mid-day trading, an increase of 56% from the average session volume of 23,311 shares. The stock had previously closed at $1.75.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on IPHA shares. Leerink Partnrs lowered Innate Pharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 18th. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target (down previously from $10.00) on shares of Innate Pharma in a research report on Thursday, September 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Innate Pharma in a research note on Wednesday, October 8th. HC Wainwright set a $5.00 price objective on shares of Innate Pharma and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of Innate Pharma in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Innate Pharma currently has an average rating of “Hold” and an average price target of $5.00.
View Our Latest Stock Analysis on Innate Pharma
Innate Pharma Price Performance
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.
The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.
Featured Stories
- Five stocks we like better than Innate Pharma
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Can Any Expenses Be Deducted From Capital Gains Tax?
- The Last Gold Bull Market
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
